Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) will be reporting earnings tomorrow afternoon. Here’s what to look for.
Jazz Pharmaceuticals beat analysts’ revenue expectations by 2.8% last quarter, reporting revenues of $1.09 billion, up 7.5% year on year. It was a strong quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and an impressive beat of analysts’ EPS estimates.
Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Jazz Pharmaceuticals’s revenue to grow 9.4% year on year to $986.6 million, improving from the 1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.66 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Jazz Pharmaceuticals has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb’s revenues decreased 5.6% year on year, beating analysts’ expectations by 3.9%, and Organon reported a revenue decline of 6.7%, topping estimates by 0.6%. Bristol-Myers Squibb traded down 1.3% following the results while Organon was also down 25.8%.
Read our full analysis of Bristol-Myers Squibb’s results here and Organon’s results here.
There has been positive sentiment among investors in the pharmaceuticals segment, with share prices up 4.9% on average over the last month. Jazz Pharmaceuticals is up 12.3% during the same time and is heading into earnings with an average analyst price target of $190.28 (compared to the current share price of $120.05).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
